Evaluation of PD-L1, PD-L2, PD-1 and cytotoxic immune response in oral lichen planus

被引:13
作者
Costa, Nadia Lago [1 ]
Goncalves, Julie Ane Maria [1 ]
de Lima, Sara Lia Goncalves [1 ]
de Arruda, Jose Alcides Almeida [2 ]
Miranda, Ana Carolina Campos [1 ]
Mesquita, Ricardo Alves [1 ,2 ]
da Silveira, Ericka Janine Dantas [3 ]
Batista, Aline Carvalho [1 ]
机构
[1] Univ Fed Goias, Sch Dent, Dept Stomatol Oral Med & Oral Pathol, Praca Univ S-N,Setor Univ, BR-74605220 Goiania, Go, Brazil
[2] Univ Fed Minas Gerais, Sch Dent, Dept Oral Surg & Pathol, Belo Horizonte, MG, Brazil
[3] Univ Fed Rio Grande do Norte, Dept Dent, Postgrad Program Odontol Sci, Natal, RN, Brazil
关键词
immunogenicity; immunohistochemical; lichen planus; mouth diseases; programmed cell death-1 ligand-2 protein; T-lymphocyte receptor; MALIGNANT-TRANSFORMATION; T-CELLS; EVASION MECHANISMS; EXPRESSION; MICROENVIRONMENT; PATHWAY; LESIONS; B7-DC;
D O I
10.1111/odi.13344
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective To investigate the expression of programmed death-ligands 1 and 2 (PD-L1, PD-L2), programmed death-1 (PD-1), CD8 and granzyme B (GrB), as well as its correlation with the severity of oral lichen planus (OLP). Materials and Methods In a collaborative study, 33 cases of OLP were evaluated according to the latest criteria proposed by the American Academy of Oral and Maxillofacial Pathology (AAOMP/2016) and were submitted to immunohistochemistry. Positivity was measured semiquantitatively (PD-L1, PD-L2) and quantitatively (PD-1, CD8, GrB). The severity of OLP was assessed according to clinical subtype, symptomatology and response to corticosteroid therapy. Results Most OLPs were considered to be negative for PD-L1 (66.6%), but high expression of PD-L2 (96.9%) by keratinocytes and immunoinflammatory cells was observed. PD-1(+) cell density/mm(2) was reduced compared to CD8(+) cells. A low cytotoxic immune response (CD8:GrB ratio) was also demonstrated. Interestingly, there were fewer GrB(+) cells in the intraepithelial region in reticular OLP compared to erosive/bullous OLP. Conclusions PD-L1/PD-1 pathways appear to be compromised in OLP due to low PD-L1 expression in most samples. In contrast, PD-L2 overexpression associated with a possible regulation of the cytotoxic immune response suggests an immune tolerance that may contribute to the chronic profile of OLP.
引用
收藏
页码:1246 / 1254
页数:9
相关论文
共 50 条
  • [41] Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia
    Ries, Jutta
    Agaimy, Abbas
    Wehrhan, Falk
    Baran, Christoph
    Bolze, Stella
    Danzer, Eva
    Frey, Silke
    Jantsch, Jonathan
    Moest, Tobias
    Buettner-Herold, Maike
    Wickenhauser, Claudia
    Kesting, Marco
    Weber, Manuel
    BIOMEDICINES, 2021, 9 (02) : 1 - 26
  • [42] The PD-1 and PD-L1 pathway in recurrent respiratory papillomatosis
    Ahn, Julie
    Bishop, Justin A.
    Roden, Richard B. S.
    Allen, Clint T.
    Best, Simon R. A.
    LARYNGOSCOPE, 2018, 128 (01) : E27 - E32
  • [43] The significance of PD-1/PD-L1 imbalance in ulcerative colitis
    Shi, Wei
    Zhang, Yu
    Hao, Chonghua
    Guo, Xiaofeng
    Yang, Qin
    Du, Junfang
    Hou, Yabin
    Cao, Gaigai
    Li, Jingru
    Wang, Haijiao
    Fang, Wei
    PEERJ, 2023, 11
  • [44] Highly Activated PD-1/PD-L1 Pathway in Gastric Cancer with PD-L1 Expression
    Saito, Hiroaki
    Kono, Yusuke
    Murakami, Yuki
    Shishido, Yuji
    Kuroda, Hirohiko
    Matsunaga, Tomoyuki
    Fukumoto, Yoji
    Osaki, Tomohiro
    Ashida, Keigo
    Fujiwara, Yoshiyuki
    ANTICANCER RESEARCH, 2018, 38 (01) : 107 - 112
  • [45] PD-1/PD-L1 pathway: current researches in cancer
    Han, Yanyan
    Liu, Dandan
    Li, Lianhong
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (03): : 727 - 742
  • [46] Targeting PD-1/PD-L1 interactions for cancer immunotherapy
    Zitvogel, Laurence
    Kroemer, Guido
    ONCOIMMUNOLOGY, 2012, 1 (08): : 1223 - 1225
  • [47] Beyond inhibition against the PD-1/PD-L1 pathway: development of PD-L1 inhibitors targeting internalization and degradation of PD-L1
    Guo, Jiazheng
    Yu, Fengyi
    Zhang, Kuojun
    Jiang, Sheng
    Zhang, Xiangyu
    Wang, Tianyu
    RSC MEDICINAL CHEMISTRY, 2024, 15 (04): : 1096 - 1108
  • [48] In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
    Reddy, Vishwanatha R. A. P.
    Mwangi, William
    Sadigh, Yashar
    Nair, Venugopal
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2019, 9
  • [49] Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma
    Jung, Hae Il
    Jeong, Dongjun
    Ji, Sanghee
    Ahn, Tae Sung
    Bae, Sang Ho
    Chin, Susie
    Chung, Jun Chul
    Kim, Hyung Chul
    Lee, Moon Soo
    Baek, Moo-Jun
    CANCER RESEARCH AND TREATMENT, 2017, 49 (01): : 246 - 254
  • [50] The PD-1:PD-L1 axis in Inflammatory Arthritis
    Canavan, Mary
    Floudas, Achilleas
    Veale, Douglas J.
    Fearon, Ursula
    BMC RHEUMATOLOGY, 2021, 5 (01)